Novel prognostic markers revealed by a proteomic approach separating benign from malignant insulinomas

Modern Pathology

Volumn 28, Issue 1, 2015, Pages 69-79

  Alkatout, Ibrahim ^a,h   Friemel, Juliane ^b,h   Sitek, Barbara ^c   Anlauf, Martin ^d   Eisenach, Patricia A ^e   Stühler, Kai ^d   Scarpa, Aldo ^f   Perren, Aurel ^g   Meyer, Helmut E ^c,h   Knoefel, Wolfram T ⁱ   Klöppel, Günter ^j   Sipos, Bence ^h,k  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c RUHR UNIVERSITY BOCHUM   (Germany)

^d HEINRICH HEINE UNIVERSITY   (Germany)

^e MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^f UNIVERSITY AND HOSPITAL TRUST OF VERONA   (Italy)

^g UNIVERSITY OF BERN   (Switzerland)

^h UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

ⁱ UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^j TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^k LEIBNIZ INSTITUT FÜR ANALYTISCHE WISSENSCHAFTEN ISAS E V   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE 1A1; BIOLOGICAL MARKER; FLUORESCENT DYE; PROTEOME; TUMOR PROTEIN; TUMOR PROTEIN D52; UNCLASSIFIED DRUG; VOLTAGE DEPENDENT ANION CHANNEL; TPD52 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; BENIGN TUMOR; CANCER PROGNOSIS; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INSULINOMA; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEOMICS; RECURRENCE FREE SURVIVAL; TISSUE MICROARRAY; TWO DIMENSIONAL GEL ELECTROPHORESIS; AGED; BIOSYNTHESIS; KAPLAN MEIER METHOD; METABOLISM; MICRODISSECTION; MIDDLE AGED; MORTALITY; PANCREAS TUMOR; PATHOLOGY; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

ADULT; AGED; BIOMARKERS, TUMOR; CHROMATOGRAPHY, LIQUID; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INSULINOMA; KAPLAN-MEIER ESTIMATE; MALE; MICRODISSECTION; MIDDLE AGED; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEOMICS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TISSUE ARRAY ANALYSIS;

EID: 84920669864     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2014.82     Document Type: Article

References (35)

1. Bosman FT, Carneiro F, Hruban RH, Theise ND (eds). WHO Classification of Tumours of the Digestive System. Chapter 124th edn. International Agency for Research on Cancer: Lyon, 2010.
2. Klöppel G, Couvelard A, Perren A, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology 2009;90:162-166.
3. Schmitt AM, Anlauf M, Rousson V, et al. WHO 2004 criteria and CK19 are reliable prognostic markers in pancreatic endocrine tumors. Am J Surg Pathol 2007;31:1677-1682.
4. Anlauf M, Gerlach P, Schott M, et al. Pathology of neuroendocrine neoplasms. Chir Z Fü r Alle Geb Oper Medizen 2011;82:567-573.
5. De Herder WW, Niederle B, Scoazec J-Y, et al. Well-differentiated pancreatic tumor/carcinoma: insulinoma. Neuroendocrinology 2006;84:183-188.
6. Sitek B, Lü ttges J, Marcus K, et al. Application of fluorescence difference gel electrophoresis saturation labelling for the analysis of microdissected precursor lesions of pancreatic ductal adenocarcinoma. Proteomics 2005;5:2665-2679.
7. Klose J, Kobalz U. Two-dimensional electrophoresis of proteins: an updated protocol and implications for a functional analysis of the genome. Electrophoresis 1995;16:1034-1059.
8. Nesterenko MV, Tilley M, Upton SJ. A simple modification of Blum's silver stain method allows for 30 minute detection of proteins in polyacrylamide gels. J Biochem Biophys Methods 1994;28:239-242.
9. Sitek B, Sipos B, Pfeiffer K, et al. Establishment of 'onepiece' large-gel 2-DE for high-resolution analysis of small amounts of sample using difference gel electrophoresis saturation labelling. Anal Bioanal Chem 2008;391:361-365.
10. Raffel A, Krausch M, Roushan K, et al. Global histone modification pattern predicts poor prognosis in organic hyperinsulinism. Horm Metab Res 2011;43:858-864.
11. Sitek B, Sipos B, Alkatout I, et al. Analysis of the pancreatic tumor progression by a quantitative proteomic approach and immunhistochemical validation. J Proteome Res 2009;8:1647-1656.
12. Klöppel G. Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer 2011;18(Suppl 1):S1-16.
13. Pelosi G, Fraggetta F, Sonzogni A, Fazio N, Cavallon A, Viale G. CD99 immunoreactivity in gastrointestinal and pulmonary neuroendocrine tumours. Virchows Arch Int J Pathol 2000;437:270-274.
14. Rigaud G, Missiaglia E, Moore PS, et al. High resolution allelotype of nonfunctional pancreatic endocrine tumors: identification of two molecular subgroups with clinical implications. Cancer Res 2001;61:285-292.
15. Jonkers YMH, Claessen SMH, Perren A, et al. Chromosomal instability predicts metastatic disease in patients with insulinomas. Endocr Relat Cancer 2005;12:435-447.
16. Speel EJ, Richter J, Moch H, et al. Genetic differences in endocrine pancreatic tumor subtypes detected by comparative genomic hybridization. Am J Pathol 1999; 155:1787-1794.
17. Barghorn A, Komminoth P, Bachmann D, et al. Deletion at 3p25.3-p23 is frequently encountered in endocrine pancreatic tumours and is associated with metastatic progression. J Pathol 2001;194:451-458.
18. Jiao Y, Shi C, Edil BH, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011;331: 1199-1203.
19. Bhat PV, Poissant L, Wang XL. Purification and partial characterization of bovine kidney aldehyde dehydrogen ase able to oxidize retinal to retinoic acid. Biochem Cell Biol 1996;74:695-700.
20. Ma I, Allan AL. The role of human aldehyde dehydrogenase in normal and cancer stem cells. Stem Cell Rev 2011;7:292-306.
21. Herreros-Villanueva M, Zhang J-S, Koenig A, et al. SOX2 promotes dedifferentiation and imparts stem cell-like features to pancreatic cancer cells. Oncogenesis 2013;2:e61.
22. Lombardo Y, Filipović A, Molyneux G, et al. Nicastrin regulates breast cancer stem cell properties and tumor growth in vitro and in vivo. Proc Natl Acad Sci USA 2012;109:16558-16563.
23. Liu S, Ginestier C, Charafe-Jauffret E, et al. BRCA1 regulates human mammary stem/progenitor cell fate. Proc Natl Acad Sci USA 2008;105:1680-1685.
24. Matsuda H, Parsons MJ, Leach SD. Aldh1-expressing endocrine progenitor cells regulate secondary islet formation in larval zebrafish pancreas. PLoS One 2013;8:e74350.
25. Li J, Feng ZC, FS-H Yeung, et al. Aldehyde dehydrogenase 1 activity in the developing human pancreas modulates retinoic acid signalling in mediating islet differentiation and survival. Diabetologia 2014;57: 754-764.
26. Shoshan-Barmatz V, Mizrachi D. VDAC1: from structure to cancer therapy. Front Oncol 2012;2:164.
27. Pedersen PL. Warburg, me and Hexokinase 2: Multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the 'Warburg Effect', i.e., elevated glycolysis in the presence of oxygen. J Bioenerg Biomembr 2007;39:211-222.
28. Pastorino JG, Hoek JB. Regulation of hexokinase binding to VDAC. J Bioenerg Biomembr 2008;40: 171-182.
29. Sun L, Shukair S, Naik TJ, Moazed F, Ardehali H. Glucose phosphorylation and mitochondrial binding are required for the protective effects of hexokinases I and II. Mol Cell Biol 2008;28:1007-1017.
30. Grills C, Jithesh PV, Blayney J, Zhang S-D, Fennell DA. Gene expression meta-analysis identifies VDAC1 as a predictor of poor outcome in early stage non-small cell lung cancer. PLoS One 2011;6:e14635.
31. Lai JC, Tan W, Benimetskaya L, Miller P, Colombini M, Stein CA. A pharmacologic target of G3139 in melanoma cells may be the mitochondrial VDAC. Proc Natl Acad Sci USA 2006;103:7494-7499.
32. Boutros R, Fanayan S, Shehata M, Byrne JA. The tumor protein D52 family: many pieces, many puzzles. Biochem Biophys Res Commun 2004;325:1115-1121.
33. Lewis JD, Payton LA, Whitford JG, et al. Induction of tumorigenesis and metastasis by the murine orthologue of tumor protein D52. Mol Cancer Res 2007;5: 133-144.
34. Byrne JA, Maleki S, Hardy JR, et al. MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome. BMC Cancer 2010;10:497.
35. Rubin MA, Varambally S, Beroukhim R, et al. Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer. Cancer Res 2004;64:3814-3822.